All In MedTech

Device Trial Radar · NCT02448160

Alfapump-albumin Replacement Therapy

Study Into the Effects of Albumin Replacement Therapy on Renal and Circulatory Function in Patients Implanted With the Alfapump

Last checked: Nov 19, 2026Latest source record: Apr 9, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

10

Planned (sponsor's estimate)

Start

Jan 2016

Primary completion

Dec 2017

Study completion Dec 2017

Sponsor

Lead sponsor
Sequana Medical N.V.Not on our public-company list
Sponsor type
Industry
First posted
May 19, 2015

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will be a single centre, open-label trial. The patients will have a diagnosis of refractory ascites and will meet specified inclusion/exclusion criteria Informed consent will be obtained from all patients. All patients will have an alfapump surgically inserted and in addition will receive 8g of salt-poor Human Albumin Solution (20%) per 1 litre of Ascites drained. This Intravenous administration will be intermittent (every month) and will take place as a day patient. Patients will also receive standard of care, which may include, but is not limited to, administration of diuretics, paracentesis and consideration for orthotopic liver transplantation.

Conditions

  • Liver Cirrhosis

Interventions

  • alfapumpDevice

    Implantation of alfapump

  • salt-poor Human Albumin solutionDrug

    Patients implanted with an alfapump will receive intermittent salt-poor human albumin solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To assess whether intermittent human albumin replacement in accordance with large volume paracentesis guidelines (8g/L ascites drained) can prevent the development of renal dysfunction, measured by serum creatinineTime frame: 3 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Royal Free Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.